Mediaboss Marketing

PRESS RELEASE: Epigenomics AG: Epigenomics Begins Trading on OTCQX Marketplace in the U.S.

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous Epigenomics AG: Epigenomics Begins Trading on OTCQX Marketplace in the U.S.

10.01.2014 / 10:00

=--------------------------------------------------------------------

- BNY Mellon to act as Principal American Liaison (PAL) for Epigenomics on OTCQX - Epigenomics' ADRs to start trading under ticker symbol EPGNY today

Berlin, Germany, and Germantown, MD, U.S.A., January 10, 2014 - Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company has been approved for trading on OTCQX.

Epigenomics' American Depositary Receipts (ADRs) began trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international exchange, produce quarterly management reports and provide their home country disclosures to U.S. investors. BNY Mellon will act as the Company's PAL on OTCQX responsible for providing professional guidance on OTCQX requirements.

Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented: 'Raising our profile in the U.S. public capital markets is an important part of our strategy as we approach the decision by the FDA regarding the approval of our blood-based colorectal cancer detection test, Epi proColon(R). We look forward to intensifying our interactions with U.S. capital markets participants and our sponsored ADR program also serves as the stepping stone to approach U.S. investors more efficiently in the future.'

Epigenomics trades in the U.S. on OTCQX under the ticker symbol 'EPGNY', where each ADR represents 5 ordinary shares. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on http://www.otcmarkets.com.

- Ends -

See the article here:
PRESS RELEASE: Epigenomics AG: Epigenomics Begins Trading on OTCQX Marketplace in the U.S.